Point72 Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$359K	Buy	14,200 +500	+4%	+$11K	﹤0.01%	3318
2026 Q1	$305K	Buy	+13,700	New	+$327K	﹤0.01%	3357
2024 Q3	–	Sell	-102,000	Closed	-$1.66M	–	1938
2024 Q2	$1.66M	Buy	102,000 +12,000	+13%	+$194K	﹤0.01%	1145
2024 Q1	$1.66M	Buy	+90,000	New	+$2.23M	﹤0.01%	1323
2021 Q2	–	Sell	-198,900	Closed	-$5.13M	–	944
2021 Q1	$5.13M	Buy	+198,900	New	+$8.76M	0.02%	560
2018 Q4	–	Sell	-200,000	Closed	-$4.15M	–	927
2018 Q3	$4.15M	Sell	200,000 -1,900,000	-90%	-$29.9M	0.02%	645
2018 Q2	$32.1M	Buy	+2,100,000	New	+$37.4M	0.13%	205
2016 Q4	–	Sell	-120,300	Closed	-$3.83M	–	672
2016 Q3	$3.83M	Buy	+120,300	New	+$4.08M	0.03%	465
2016 Q2	–	Sell	-450,000	Closed	-$12.6M	–	706
2016 Q1	$12.6M	Buy	+450,000	New	+$9.81M	0.1%	245

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management's ACAD Position: Q2 2026 in Review

Point72 Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 5.6% in Q2 2026, selling an estimated $3.18M and leaving 2,433,168 shares worth $61.6M. The position accounts for 0.07% of the portfolio, ranked #354.

Point72 Asset Management first reported a position in ACAD in Q2 2014 and has held it in 39 quarters since. The position peaked at $97.9M in Q1 2018. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Point72 Asset Management held 2,433,168 shares of Acadia Pharmaceuticals worth $61.6M as of Q2 2026.
Point72 Asset Management sold 144,748 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.18M.
Acadia Pharmaceuticals made up 0.07% of Point72 Asset Management's portfolio in Q2 2026, its #354 holding.
Point72 Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 39 quarters since.
Point72 Asset Management's Acadia Pharmaceuticals position peaked at $97.9M in Q1 2018.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.